AVEO Pharmaceuticals Inc

AVEO Pharmaceuticals — Investor Presentation (October 2019)

34 slides from AVEO Pharmaceuticals's investor presentation, Oct 3, 2019

  1. Slide 1: AVEO Overview October 2019

    AVEO Overview October 2019 Exhibit 99 .1

  2. Slide 2: Cautionary Note Regarding Forward-Looking Statements

    Cautionary Note Regarding Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained

  3. Slide 3: AVEO Oncology: Strategy for Value Creation

    AVEO Oncology: Strategy for Value Creation Value Enhancing Partnerships Deep Pipeline Addressing Significant Unmet Needs Multiple oncology and non-oncology pipeline opportunities FOTIVDA® (tivozanib) – IO Combinations (RCC, HCC, other) Selective VEGFR TKI has potential to enable unique tolerability

  4. Slide 4: Pipeline overview

    Clinical Preclinical Phase 1 Phase 2 Phase 3 Regulatory Filing Marketed Partner Tivozanib (RCC) VEGFR 123 TKI Tivozanib (HCC) VEGFR 123 TKI Ficlatuzumab HGF MAb AV-203 (CAN017) ERBB3 MAb Multiple Potential Opportunities for Value Creation TIVO-1 (Phase 3 Registration Study in 1st Line RCC) TIVO-3 (P

  5. Slide 5: Financial Highlights

    Financial Highlights Cash on hand to fund planned operations into 3Q 2021* $40.2M in cash, cash equivalents, and marketable securities as of 2Q 2019 $25.0M upfront payment from Kyowa Kirin received in 3Q 2019 Kyowa Kirin buy back of tivozanib non-oncology rights: $25.0M upfront payment Waiver of the

  6. Slide 6: FOTIVDA (tivozanib) TIVO-3 Pivotal Phase 3 Study

    FOTIVDA® (tivozanib) TIVO-3 Pivotal Phase 3 Study

  7. Slide 7: Tivozanib: VEGFR 1, 2 and 3 Tyrosine Kinase Inhibitor

    Tivozanib: VEGFR 1, 2 and 3 Tyrosine Kinase Inhibitor Potent, selective inhibitor of VEGFRs 1, 2 and 3 with a long half-life that is designed to optimize blockade while minimizing off-target toxicities1,2 1 Nakamura K et al. Cancer Res 2006;66:9134–9142. 2 Eskens FA et al. Clin Cancer Res 2011;17:71

  8. Slide 8: TIVO-3: Study Design

    TIVO-3: Study Design N = 350 F Recurrent/metastatic RCC Failed at least two prior regimens including VEGFR-TKI Stratified by prior regimen (TKI-TKI; TKI-PD1; TKI-Other) ECOG PS 0 or 1 RANDOMIZE 1:1 tivozanib sorafenib 1O: PFS 2O: OS, ORR, DoR, Safety and Tolerability for ITT 60% 3rd line patients, 4

  9. Slide 9: TIVO-3: Superior PFS and ORR

    | TIVO-3: Superior PFS and ORR ‘Median PFS, mo (95% Cl) Tivozanib 5.6 (5.3, 7.3) Sorafenib 3.9 (3.7,5.6) HR, 0.73 (95% Cl: 0.56, 0.94) P=0,0165 2yr PFS e Survival Probability | 18% * Statistically significant benefit in ORR, p=0.02 * Durable responses with tivozanib: + 55% remaining in response past

  10. Slide 10: Progression-Free Survival – Key Subgroups

    Progression-Free Survival – Key Subgroups* *Final analysis, as of Oct 4, 2018 Tivozanib Sorafenib Tivozanib Sorafenib Porta et al. ASCO 2019

  11. Slide 11: Treatment-Related Adverse Events

    Treatment-Related Adverse Events* (≥20% frequency in either arm) Tivozanib (N=173)^ Sorafenib (N=170)^ Preferred Term All Grades % Grade 3/4 % All Grades % Grade 3/4 % Treatment Related AEs 84 44 94 55 Hypertension 36 20 25 14 Diarrhea 33 2 50 9 Fatigue 29 4 19 5 Decreased Appetite 26 4 21 2 Dysphon

  12. Slide 12: Tolerability Results

    Tivozanib (N=173)^ Sorafenib (N=170)^ Mean Number of Cycles Initiated 10.3 6.3 AEs Leading to Dose Reductions (%) 24 38 AEs Leading to Dose Interruption (%) 48 63 Treatment Related SAEs (%) 11 10 Treatment Related Deaths (%) 0 0 Deaths within 30 days of Tx (N) 15 12 Exposure Adj Deaths per Month of

  13. Slide 13: Patients Benefiting Most from Tivozanib Underrepresented in Preliminary OS Analysis

    Patients Benefiting Most from Tivozanib Were Underrepresented in Preliminary OS Analysis 2yr PFS 18% 5% 28% 1yr PFS 11% TIVO-3 PFS Curve (ITT) 72% of OS events in preliminary analysis from patients with <4 months of PFS (Oct 4, 2018 Data Cut)

  14. Slide 14: Secondary Endpoint – Overall Survival

    Secondary Endpoint – Overall Survival Initial OS Analysis (Oct 4, 2018): HR* >1.00 Analysis based on 183 OS events Prespecified OS Analysis Update (Aug 15, 2019): HR*=0.99 Analysis based on 227 OS events 95% CI: 0.76-1.29; p=0.95 44 additional events since Oct 4, 2018 data cut 16 tivozanib events an

  15. Slide 15: TIVO-3 Conclusions

    TIVO-3 Conclusions Tivozanib significantly improves PFS and ORR compared to sorafenib in patients with treatment-refractory advanced RCC Tivozanib was superior in patients previously treated with checkpoint inhibitors as well as two VEGFR-TKIs Responses with tivozanib were more durable than sorafeni

  16. Slide 16: PD-1 Combination Opportunities

    PD-1 Combination Opportunities

  17. Slide 17: Tivozanib Properties May Provide Advantages in Combination with IO Therapy

    Tivozanib Properties May Provide Advantages in Combination with IO Therapy Nakamura K et al. Cancer Res 2006;66:9134–9142. Pawlowski N et al. AACR 2013. Poster 3971. Hammers, Emerging VEGF-I/O Combinations, ASCO 2017

  18. Slide 18: TiNivo Phase 1/2 Data Presented at ESMO 2019

    Phase 2 Data Presented at ESMO in September 2019 Tivozanib (1.0 mg/day) QD/21 days + nivolumab 240 mg Q2 weeks N = 6 ECOG PS ≤ 1 and life expectancy ≥ 3 months Tivozanib (1.5 mg/day) QD/21 days + nivolumab 240 mg Q2 weeks Tivozanib (1.5 mg/day) QD/21 days + nivolumab 240mg Q2 weeks Phase 1 Phase 2 N

  19. Slide 19: ESMO 2019: Encouraging Safety Results

    ESMO 2019: Encouraging Safety Results Hypertension (52%) is the most common grade 3/4 AE Only 17% of patients required a dose reduction Barthelemy et al. ESMO 2019

  20. Slide 20: ESMO 2019: Encouraging Efficacy

    ESMO 2019: Encouraging Efficacy 56% ORR and 96% DCR 72% had tumor shrinkage ≥ 25% 4% of patients had a complete response mPFS of 18.9 months Results suggest additive or synergistic efficacy for tivozanib + PD-1 Barthelemy et al. ESMO 2019

  21. Slide 21: Combination of PD-1 + VEGF TKIs: Promising Responses

    Combination of PD-1 + VEGF TKIs: Promising Responses, All Phase 3 Currently 1st Line Efficacy N (%) Tivozanib + Nivolumab1 Total N=25 Pembro + Lenvatinib2 Total N=30 Cabo + Nivo or IpiNivo3 Total N=13 Axitinib + Pembro4 Total N=52 Axitinib + Avel5 Phase 3 Total N=442 (ITT) Axitinib + Pembro6 Total N

  22. Slide 22: TiNivo – Strong Efficacy in Treatment Naive and Previously Treated Patients

    TiNivo – Strong Efficacy Seen in Both Treatment Naive and Previously Treated Patients Treatment Naïve (12) Pre-Treated (13*) Overall (25) CR 8% - 4% PR 42% 62% 52% SD 42% 38% 40% PD 8% - 4% ORR (CR+PR) 50% 62% 56% DCR (CR+PR+SD) 92% 100% 96% mPFS 18.9 mo (4.7, NR) NR (11.0, NR) 18.9 mo (16.4, NR) TX

  23. Slide 23: Immuno-Oncology Clinical Collaboration with AstraZeneca

    Immuno-Oncology Clinical Collaboration with AstraZeneca Clinical Rationale: Single agent activity demonstrated for tivozanib and durvalumab in HCC2,3. Combination of two agents has potential to show enhanced efficacy and tolerability profile among TKI/IO regimens. Planned Phase 1/2 study: Costs shar

  24. Slide 24: Tivozanib Commercial Opportunity

    Tivozanib Commercial Opportunity

  25. Slide 25: Significant Potential Commercial Opportunity for Tivozanib in the United States

    If Approved, Significant Potential Commercial Opportunity for Tivozanib in the United States 1st Line Market (est. 2020) ~$1.6B1 2nd Line Market (est. 2020) ~$700M1 3rd Line+ Market (est. 2020) ~$300M1 Expect opportunity to expand Potential to be first agent indicated for 3rd & 4th line Only pivotal

  26. Slide 26: Potential Relevance of Tivozanib in Refractory RCC

    Potential Relevance of Tivozanib in Refractory RCC Source: AVEO blinded Third-Party U.S. Oncologist Market Research using approximate TIVO-3 PFS and AE profile - Dec 2018 n=100 Treatments with proven efficacy are needed for patients who have failed 2 or more lines of treatment for RCC I prefer using

  27. Slide 27: FOTIVDA Commercialization in EU and ROW

    First-line treatment for patients with good or intermediate risk Second-line patients following TKIs Launched in Germany, Spain and UK Approved in New Zealand https://www.esmo.org/Guidelines/Genitourinary-Cancers/Renal-Cell-Carcinoma FOTIVDA® Commercialization in EU and ROW This Photo by Unknown Aut

  28. Slide 28: Pipeline and Near-Term Milestones

    Pipeline and Near-Term Milestones

  29. Slide 29: Tivozanib

    Tivozanib * Does not include potential PTE up to 5 yr max VEGFR 1, 2 and 3 Tyrosine Kinase Inhibitor Launched in Europe by EUSA as FOTIVDA® in first line RCC in November 2017 TIVO-3 study on-going for potential U.S. registration for RCC Tivozanib + OPDIVO® Phase 1/2 in collaboration with BMS complet

  30. Slide 30: Ficlatuzumab

    Ficlatuzumab * Does not include potential PTE up to 5 yr max HGF Inhibitory Antibody with Optimal Blockade of c-Met AML: Phase 1/2 trial of ficlatuzumab and cytarabine in refractory AML patients (n=18) Demonstrated 50% CR in patients refractory to initial therapy Randomized Phase 2 in planning SCCHN

  31. Slide 31: CAN017 (AV-203): Anti-ERBB3 MAb with Broad Therapeutic Potential

    Anti-ERBB3 Mab with Broad Therapeutic Potential CANbridge to fund clinical development through Phase 2 POC study Potential additional $40.0M development and regulatory/$90.0M commercial milestone Tiered low double-digit royalties for ex-NA rights Planned indication: squamous cell esophageal cancer (

  32. Slide 32: AV-380: First-in-Class Anti-GDF15 MAb for Cachexia

    First-in-Class, Anti-GDF15 MAb for Cachexia Cachexia affects approximately 5 million patients in the U.S. alone; affects up to 80% of advanced cancer patients and is responsible for approximately 30% of all cancer deaths1,2 Pre-clinical development underway to enable planned IND submission in 2020 C

  33. Slide 33: AVEO Key Near Term Potential Milestones

    AVEO Key Near Term Potential Milestones Tivozanib (VEGFR 1, 2 and 3 TKI) 2H19 1H20 2H20 TIVO-3 OS Update / Regulatory Discussion DEDUCTIVE HCC Ph 1/2 (Durvalumab + Tivo) Initiation TiNivo RCC (Nivolumab + Tivo) Final PFS Presentation Ficlatuzumab (HGF Inhibitory Antibody) 2H19 1H20 2H20 AML Randomiz

  34. Slide 34: AVEO Overview October 2019

    AVEO Overview October 2019

AVEO Pharmaceuticals — Investor Presentation (October 2019) on 6ix